Neurocrine Biosciences Inc vs Ryanair Holdings plc — how do they compare? Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B), while Ryanair Holdings plc trades at $60.03 (market cap $29.63B). The key difference: Ryanair Holdings plc is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.51% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | RYAAY | |
|---|---|---|
Market Cap | $16.46B | $29.63B |
Sector | Health | Industrials |
52-Week High | $185.50 | $73.82 |
52-Week Low | $123.10 | $53.24 |
Enterprise Value | $16.48B | $26.61B |
Dividend Yield | — | 1.51% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →